The webinar will focus on international survivorship guidelines surveillance recs on SMN screening- specifically breast and colorectal cancer and will provide more background and rationale for changes in the recommendations in new guidelines.  

Speakers:

Neel S. Bhatt, MBBS, MPH, Fred Hutchinson Cancer Center/ University of Washington 

Rachel Phelan, MD, MPH, Medical College of Wisconsin/Children’s Wisconsin

Seth Rotz, MD, Cleveland Clinic Children’s Hospital

The ASTCT Pharmacy SIG November 2024 Journal Club will air on Wednesday, November 20, 2024 at 2 pm CST/3 pm EST. This webinar consists of two, 30-minute journal club presentations, which include 20 minutes for the presentation and 10 minutes for discussion and a Q&A session. In this Journal Club session, Drs. Kasper and Atkins will present on two articles related to: (a) Axatilimab in recurrent or refractory cGvHD and (b) safety and efficacy of maribavir versus valganciclovir inpatients with CMV post-HCT. This session is intended for pharmacists and other members of the health care team who are involved in managing patients undergoing hematopoietic stem cell transplant or cell therapy.

Presenters & Articles:

Ryan Kasper, PharmD

PGY-2 Pharmacy Resident

University of Pennsylvania

Article: Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease

Payton Atkins, PharmD

PGY-2 Pharmacy Resident

University of Kentucky

Article: Treatment for First Cytomegalovirus Infection Post-Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blinded, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir

Session Learning Objectives:

Upon completion of the activity, participants should be able to:

• Summarize current treatment options for chronic graft-versus-host disease (cGVHD) following allogeneic stem cell transplant
• Analyze the safety and efficacy of axatilimab at various doses in patients with relapsed or refractory cGVHD
• Assess the place in therapy of axatilimab based on the data presented in the AGAVE-201 study
• Discuss current standard of care for the management of CMV in patients post-HCT
• Analyze the AURORA trial and associated implications for clinical practice
• Address limitations of the AURORA trial and future research directions for CMV management

ACCREDITED PROVIDER

This activity is jointly provided by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT).

In support of improving patient care, this activity has been planned and implemented by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION

Pharmacists

This knowledge-based activity qualifies for 1.0 contact hours (0.10 CEUs) of continuing pharmacy education credit. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

All other healthcare professionals completing this course will be issued a statement of participation.

The full CE information for this session can be viewed here.

The Pharmacy HCT Core Topics Connection Live Session will air on Tuesday, November 12, at 2 pm CT/3 pm ET. This live session will focus on two core topics in hematopoietic cell transplantation and cellular therapy- Acute GVHD and Chronic GVHD. The faculty below will answer questions about their respective topics and share their experiences from their institutions. The target audience is PGY2 Oncology Pharmacy Residents, but is open to all trainees practicing or interested in transplantation and cellular therapy. This webinar will not be recorded. 

Live Session Faculty:

Acute Graft vs Host Disease

C. Brooke Adams, PharmD, BCOP

Clinical Pharmacy Specialist- Blood and Marrow Transplantation and Cellular Therapy

Orlando Health Cancer Institute

JoEllen Weilnau, PharmD

Clinical Pharmacy Coordinator- Hematology/Oncology/Bone Marrow Transplant

Akron Children's Hospital

Chronic Graft vs Host Disease

Rebecca Gonzalez, PharmD, BCOP

Clinical Pharmacist Specialist- Blood and Marrow Transplantation-Cellular Immunotherapy 

Moffitt Cancer Center

Elizabeth R. Eubanks, PharmD, MPH, BCPS, BCOP

Clinical Pharmacist Practitioner- Ambulatory Adult Bone Marrow Transplant

Duke Blood Cancer Center

This educational offering will focus on core topics in hematopoietic cell transplantation (HCT) and cellular therapy. The target audience is PGY2 Oncology Pharmacy Residents, but participation is open to all pharmacists or pharmacy trainees practicing or interested in transplantation and cellular therapy.  

Topics:

- Graft-versus-Host Disease (GVHD) – Presented by Zahra Mahmoudjafari, PharmD, BCOP, DPLA and Rebecca Gonzalez, PharmD, BCOP
- Infection Prophylaxis in HCT – Presented by Arpita Shah Gandhi, PharmD, BCOP and Dennis Marjoncu, PharmD, BCOP
- Chimeric Antigen Receptor (CAR) T-cell Therapies – Presented by Katie S. Gatwood, PharmD, BCOP and May T. Aziz, PharmD, BCOP
- Conditioning Regimens Used in Hematopoietic Cell Transplantation – Presented by Binni Kunvarjee, PharmD, BCOP, Maggie Nelson, PharmD, BCOP, and Vinita Pai, PharmD, MS  

Each module includes a recorded presentation, a post-test, a brief evaluation, and a certificate of completion.

Please join us for the ASTCT Pharmacy SIG Career Search Panel on Wednesday, October 23th at 2 p.m. CDT/ 3 p.m. EDT.  This live session will feature a panel of pharmacists in traditional and non-traditional oncology pharmacy roles discussing their respective career paths. The goal of this session is to assist new and current pharmacy practitioners with navigating their career journeys by allowing them to engage with oncology pharmacists working in a variety of practice settings. This event is open to all healthcare professionals who are members and non-members of ASTCT. We hope to see you on October 23!  

Panelists: 

• Amber Clemmons PharmD, BCOP, FHOPA - Clinical Professor University of Georgia College of Pharmacy, BMT Clinical Pharmacist at Wellstar-MCG Health, PGY2 Oncology Residency Director UGA/Wellstar-MCG Health   
• Julianna Roddy-McLean, PharmD, BCOP - Hematology Regional Medical Scientific Director at Merck      
• LeAnne Kennedy, PharmD, BCOP, CPP, FHOPA - Atrium Health Wake Forest Baptist PGY2 Oncology Residency Program Director, Oncology Clinical Manager at Atrium Health Wake Forest Baptist, Pharmacy Clinical Specialist in Stem Cell Transplant and Cellular Therapy, HOPA President  
• David DeRemer, PharmD, BCOP, FCCP, FHOPA - Clinical Professor at the University of Florida College of Pharmacy and the Assistant Director of Experimental Therapeutics Group at the University of Florida Health Cancer Center  
• Kelly Gaertner Brandt, PharmD, BCOP, BCPS - Oncology Clinical Pharmacy Specialist Allegheny Health Network Cancer Institute

The ASTCT Payor Relations Committee will host the webinar, 'Immune Effector Cell Therapies: Best Practices for Financial and Administrative Operations Success,' on October 10th from 11-12 p.m. CDT. This webinar will provide guidance on the unique patient authorization workflows and administrative oversight to implement and operate a successful immune effector cell therapy program. Faculty from the Payor Relations Committee will review best practices for establishing interdisciplinary workflows, focusing on institutional staff roles and participation, common pitfalls steps required to ensure expected reimbursement. This is a great chance for new centers to learn how experienced centers have evolved their approach to administrative workflows for these complex therapies. This webinar is free and open to ASTCT members and non-members.

Faculty:

Amy Emmert, MScPH; Executive Director for Cellular Therapy External Affairs at Dana Farber Cancer Institute

Cynthia Devroy, Manager, Oncology Business Operations, Northside Hospital

Catherine Cardona, Program Analyst, Blood and Marrow Transplant and Cellular Therapies Program, The University of Kansas Cancer Center

Gary Goldstein, Senior Manager, BMT and Cellular Therapy Program, Stanford Health Care

This third webinar of 2024 presented by the Palliative Care SIG will focus on lessons learned in the field and important research questions that must be answered in the future to further advance the science of palliative and supportive care to meet the needs of patients throughout the continuum of the illness.

Speakers:

Areej El-Jawahri, MD. Massachusetts General Hospital

Susan McInnes, MD, Cleveland Clinic

Effie Petersdorf, MD, University of Washington

Moderator:

Christina Ullrich, MD, MPH, Dana-Farber Cancer Institute

The 2024 CAR T Webinar Series debuted in June 2024, highlighting the Best of CAR T at the 2024 Tandem Meetings and new developments in CAR T Treatments. Recordings and slides from the live webinars have been posted here for your easy viewing.

Thank you to Johnson & Johnson and Legend Biotech for their generous support of this webinar series.

The New Developments in CAR T Treatments webinar is the second and final session in this two-part CAR T webinar series. This session aired on Tuesday, September 10, at 12 p.m. CDT and featured two presentations from Drs. Bachanova and Rouce on new developments in NK Cells and Point of Care Manufacturing. This hour-long webinar had two twenty-minute talks with the remaining time used for audience Q&A. The session is open and free to all ASTCT members and non-members. 

Topics and Speakers:

NK Cells

Veronika Bachanova, MD, PhD; University of Minnesota

Point of Care Manufacturing

Rayne Rouce, MD, BS; Baylor College of Medicine/Texas Children's

Thank you to Johnson & Johnson and Legend Biotech for their generous support of this webinar series.

Join ASTCT Director of Government Relations, Alycia Maloney, JD and Reimbursement and Policy Advisors from Nimitt Consulting for a webinar on Medicare rule updates on August 14 at 12 p.m. CDT/1 p.m. EDT. 

This webinar will cover:

• FY 2025 Inpatient Prospective Payment System (IPPS) Final Rule:
  • Final payment rates and policies for key MS-DRGs for Stem Cell Transplant MS-DRGs (014, 016 and 017) and CAR-T and Other Immunotherapies (MS-DRG 018)
  •  Final decisions on the CMS proposal for changes to the New Technology Add-on Payment (NTAP) for gene therapies for Sickle Cell Disease
  • Final outlier fixed loss threshold and market basket update amounts
• Outpatient Prospective Payment System (OPPS) Proposed Rule:
  • Payment updates to CAR-T and SCT codes
• Medicare Physician Fee Schedule (MPFS) Proposed Rule:
  • New codes and payment updates applicable to ASTCT member physicians

There will be a Q&A section at the end of the webinar, so be sure to register and submit any questions in advance that you would like answered during the webinar to info@astct.org. If you are unable to join, the recording will be made available. 

Please consider sharing this webinar with your network of doctors, administrators, providers, or any other colleagues that may be interested.